Clinical presentation, natural history and therapeutic approach in - - PowerPoint PPT Presentation

▶
clinical presentation natural history and therapeutic
SMART_READER_LITE
LIVE PREVIEW

Clinical presentation, natural history and therapeutic approach in - - PowerPoint PPT Presentation

Oct 08, 2022 666 likes •913 views

Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor (SFT): a retrospective analysis Tim Wessels, Iris Timmermans, Daphne Hompes, Marguerite Stas, Veerle Boecxstaens, Paul de Leyn, Willy

slide-1
SLIDE 1

Tim Wessels, Iris Timmermans, Daphne Hompes, Marguerite Stas, Veerle Boecxstaens, Paul de Leyn, Willy Coosemans, Dirk Van Raemdonck, Esther Hauben, Raf Sciot, Paul Clement, Oliver Bechter, Benoit Beuselinck, F. J. Sherida H. Woei-A-Jin, Herlinde Dumez, Patrick Schöffski

Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor (SFT): a retrospective analysis

slide-2
SLIDE 2

Disclosure

  • No personal conflict of interest, only

institutional

slide-3
SLIDE 3

Epidemiology of SFT

  • RARECARE: Estimated incidence of

SFT is less than 0.1 per 100.000 person-years¹

  • Frequency of SFT is less than 2% of all

Soft Tisue Sarcoma (STS)²

  • STS itself account for only 1% of all

new diagnosed malignancies²

¹Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49(3):684-95. ²Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057-68.

slide-4
SLIDE 4

History of SFT

  • 1931: 5 clinical cases of SFT¹
  • 1942: Hemangiopericytoma (HPC)²
  • 2013: Identical genetic alteration:

NAB2-STAT6 gene fusion³

¹Klemperer P, Coleman BR. Primary neoplasms of the pleura. A report of five cases. Am J Ind Med. 1992;22(1):1-31. ²Stout AP, Murray MR. Hemangiopericytoma: A Vascular Tumor Featuring Zimmermann's Pericytes. Ann Surg. 1942;116(1):26-33. ³Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125(5):651-8

  • Localized fibrous tumor of

the pleura

  • Localized mesothelioma
  • Localized benign fibroma
slide-5
SLIDE 5

Clinical presentation and risk assesment of SFT

  • Unpredictable clinical behaviour
  • Doege-Potter syndrome (IGF2): 4%¹ˉ²
  • Multiple risk stratification models

¹Fung EC, Crook MA. Doege-Potter syndrome and 'big-IGF2': a rare cause of hypoglycaemia. Ann Clin Biochem. 2011;48(Pt 2):95-6. ²Briselli M, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer. 1981;47(11):2678-89..

De Perrot et al, Ann Thorac Surg. 2002 Tapias et al. Chest. 2015 Demicco EG, Mod Pathol. 2012

slide-6
SLIDE 6

Treatment options of SFT

  • Treatment

– Surgery: R0 – Radiotherapy:

– (neo)-adjuvant? – Definite (60Gy) – palliative (39Gy)¹

– Systemic therapy: Empirical: STS based

– anthracycline mPFS: 4m > ifosfamide mPFS: 3m² – pazopanib³

¹ Haas RL, Walraven I, Lecointe-Artzner E, Scholten AN, van Houdt WJ, Griffin AM, et al. Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. Int J Radiat Oncol Biol Phys. 2018;101(5):1226-33. ² Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, et al. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013;49(10):2376-83 ³ Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(1):134-44

slide-7
SLIDE 7

Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: a retrospective analysis

slide-8
SLIDE 8

Materials and methods

  • Review of SFT/HPC pts 01/12/1990

and 30/09/2017

  • Sarcoma database LECTOR
  • Definitions
  • OS: Interval between first diagnosis of local recurrence/ metastastatic

disease and death all causes

  • PFS: Interval between day of primary surgery until the confirmation of

a local or metastatic recurrence

  • Response rates: Calculated based on investigator assessment at

moment of evaluation (Stable Disease (SD), Partial Response (PR), Progressive Disease(PD))

slide-9
SLIDE 9

Patient characteristics

2124 STS pts were included in our sarcoma database Prevalence of SFT: 4.4%

Patients 94 Age (years) 56 (16-85) Sex Male 52 (55%) Female 42 (45%) Follow up (years) 4.7 (0.1-21.53 )

slide-10
SLIDE 10

Primary site of SFT

slide-11
SLIDE 11

Clinical presentation & diagnosis

  • Symptomatology highly variable
  • Hypoglycemia: 2 patients (2.1%)

(Doege-Potter syndrome )

  • No pathognomonic radiological signs
  • 7.4% SFT was written in a radiological

report

slide-12
SLIDE 12

Prognosis and recurrence

n (%) Patients 94 Synchronous metastasis 6 (6.4) Primary resection 86 (91.5) Local recurrence 23 (26.7) Metachronous metastasis 26 (30.2) No recurrence 37 (43.0)

slide-13
SLIDE 13

Overall survival

Overall survival

50 100 150 200 250 300 25 50 75 100

Time (months) Cumulative proportion survival (%)

n= 94 mOS: 56.0m (0.3-258.3)

slide-14
SLIDE 14

Local recurrence

n= 23 (26.7%) mPFS: 35.5m (1.0-153.8) mOS 45.1m (4.7-118.2)

slide-15
SLIDE 15

Metastatic recurrence

n= 26 (30.2%) mPFS= 36.0m (0.1-157.1) n= 32 mOS= 19.0m (0.3-149.0)

slide-16
SLIDE 16

Treatment: Surgery

n (%) Primary surgery 86 R0 39 (45.5) R1 6 (7) Wider resection 2 (33.3) Rx 41 (39.1)

R0: microscopic complete resection R1: microscopic residual tumor Rx: unknown resection status

slide-17
SLIDE 17

Treatment: Radiotherapy

n (%) Primary resection 86 Adjuvant radiotherapy 14 (16.3) local recurrence 1 (7.1) metastatic recurrence 5 (35.7)

slide-18
SLIDE 18

Treatment: Systemic therapy

n (%) Patients 94 Systemic therapy 28 (29.8) neoadjuvant 2 (2.1) palliative 24 (25.5) neoadjuvant and palliative 2 (2.1)

slide-19
SLIDE 19

Treatment: Systemic therapy

n=24 mOS: 24.0m (3.2-84.4)

slide-20
SLIDE 20

Treatment: Systemic therapy

n=26 n=16 n=10

mPFS: 4.7m (0.4-23.8)

slide-21
SLIDE 21

Treatment: Systemic therapy

Response rates based on investigator opinion at first and second response evaluation: PR: Partial Response, SD: Stable Disease, PD: Progressive Disease, NA: data Not Available, x: No patients with this reponse, †vascular response, no volume response, *therapy stop due to intolerance

PR SD PD NA PR SD PD NA 1st line: doxorubicin (n=15) 2/15 4/15 7/15 2/15 2/6 1/6 3/6 x 2nd line: pazopanib (n=5) 3/5 x 1/5 1/5 1/3 1/3 1/3 x ifosfamide (n=5) x x 4/5 1/5 x x x x dacarbazine (n=2) x 1/2 1/2 x x x 1/1 x 3rd line: pazopanib (n=4) 1/4† 2/4 1/4 x x 1/3 1/3 1/3* 4th line: trabectedin (n=3) x 2/3 1/3 x x 2/2 x x

First response evaluation Second response evaluation Therapy (number of patients)

slide-22
SLIDE 22

Conclusion

  • Highly variable clinical course
  • Surgery can be curative, but risk of

recurrence is high (local 26.7%, distant 30.2%)

  • Palliative systemic traetment is associated

with a low RR (13.3%) en PFS (4.7m)

  • Highest RR observed with pazopanib in 2nd

and 3rd line

  • Sample size is too small to draw practice

changing conclusions

RR: Response rate

slide-23
SLIDE 23

Tim Wessels, Iris Timmermans, Daphne Hompes, Marguerite Stas, Veerle Boecxstaens, Paul de Leyn, Willy Coosemans, Dirk Van Raemdonck, Esther Hauben, Raf Sciot, Paul Clement, Oliver Bechter, Benoit Beuselinck, F. J. Sherida H. Woei-A-Jin, Herlinde Dumez, Patrick Schöffski

Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: a retrospective analysis